West Pharmaceutical Services Inc

West Pharmaceutical Services Inc(WST)股票分析

$392.150

-1.882 (-0.48%)收盘时

Loading chart…
最高
394.175
开盘
391.600
成交量加权均价
392.02
成交量
718.05K
市值
23.95B
最低
389.720
成交额
281.49M
企业价值/息税折旧摊销前利润(TTM)
27.93

West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies.

AI 分析 of West Pharmaceutical Services Inc (WST)

买入

West Pharmaceutical Services Inc is a good buy right now, trading at $384.02 with a strong recent performance of +4.92% over the last 5 days and a year-to-date change of +38.94%. The company has shown robust growth, with Q2 2026 sales increasing to $872 million, a 13.8% rise, and an adjusted EPS of $2.37, exceeding expectations by $0.29. However, the RSI is at 75.786, indicating it may be overbought, which is a risk to consider.

分析师评级(7)

-11.08% 下跌空间
买入
4 买入
2 持有
1 卖出
当前: 392.15
最低
285.00
平均
348.70
最高
375.00

Barclays

2026-10-07

目标价

$440

增持

Morgan Stanley

2026-09-22

目标价

$400

增持

UBS

2026-09-09

目标价

$415

买入

Citi

2026-08-03

目标价

$412

买入

Evercore ISI

2026-07-27

目标价

$425

跑赢大盘

估值指标

West Pharmaceutical Services Inc(WST)当前预期市盈率为 37.04,5 年平均预期市盈率为 41.18。

预期市盈率

合理
5 年均值 P/E
41.18
当前P/E
37.04
高估
47.97
低估
34.39

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
26.82
当前EV/EBITDA
27.93
高估
31.73
低估
21.91

预期市销率

合理
5 年均值 P/S
7.50
当前P/S
7.72
高估
9.08
低估
5.93

Alphio AI 对 WST 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%WST

$201.68

情景价格

基

基准

基准 · 50%WST

$194.98

情景价格

悲

悲观

悲观 · 25%WST

$174.26

情景价格

持有 WST 的大户

B

Birch Hill Investment Advisors LLC

+ 持有WST

+4.97%

3个月收益率

T

The Olayan Group

+ 持有WST

+3.82%

3个月收益率

B

Bill & Melinda Gates Foundation Asset Trust

+ 持有WST

+3.39%

3个月收益率

L

Local Pensions Partnership Investments Ltd

+ 持有WST

+3.13%

3个月收益率

R

Royal London Unit Trust Managers Limited

+ 持有WST

+2.36%

3个月收益率

A

AMI Asset Management Corp

+ 持有WST

+1.73%

3个月收益率

WST 常见问题 —— 由 Alphio AI 解答

West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

West Pharmaceutical Services Inc is a good buy right now, trading at $384.02 with a strong recent performance of +4.92% over the last 5 days and a year-to-date change of +38.94%. The company has shown robust growth, with Q2 2026 sales increasing to $872 million, a 13.8% rise, and an adjusted EPS of $2.37, exceeding expectations by $0.29. However, the RSI is at 75.786, indicating it may be overbought, which is a risk to consider.

7 analysts cover WST: 4 rate it Buy, 2 Hold and 1 Sell. The average price target is 348.70.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易